| Name | Title | Contact Details |
|---|
Mile Hi Foods, Mile Hi Bakery, Mile Hi Warehousing and Logistics, Mile Hi Truck Shop and the Taddonio Family Foundation
Farm Star is a Seabrook, NH-based company in the Business Services sector.
Dixie Messer Mirror Glass is a Greer, SC-based company in the Business Services sector.
TrinCan is engaged in oil and gas production and exploration, as well as mining exploration. The Company holds non-operating working interests of between 25 and 50 percent in a group of oil leases 40 kilometres south of Lloydminster, Saskatchewan, with net production of between 20 and 30 barrels of oil per day. It also holds 93.3% working interest on a lease on 1¾ sections in northwestern Alberta, referred to as the Nipisi project. In mining exploration, the Company has a 60% working interest in a group of optioned properties at Tashota, 215 kilometres northeast of Thunder Bay, Ontario. The 12,000-acre Tashota Project includes a gold-bearing zone known as the Paulpic deposit, which has a NI43-101 compliant inferred mineral resource of 68,900 ounces of gold at a grade of 8.24 grams of gold per tonne. The Company also holds an option to acquire 100% of the 920-acre Maki gold property near Beardmore, Ontario, as well as a 100% interest in the Opinaca 2 gold prospect covering approximately 18,000 acres in the James Bay area of northern Québec. The Opinaca 2 property is 15 kilometres southwest of Goldcorp's Éléonore/Roberto gold deposit, scheduled to commence production in 2014.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN